ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) Short Interest Down 27.1% in January

ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) was the recipient of a large decline in short interest in January. As of January 31st, there was short interest totalling 8,600 shares, a decline of 27.1% from the January 15th total of 11,800 shares. Based on an average daily trading volume, of 12,300 shares, the short-interest ratio is currently 0.7 days.

ProShares UltraShort Nasdaq Biotechnology Stock Up 0.5 %

Shares of BIS stock traded up $0.09 during trading hours on Friday, reaching $16.57. 12,941 shares of the company traded hands, compared to its average volume of 8,648. The firm has a 50-day moving average price of $17.34 and a 200 day moving average price of $16.04. ProShares UltraShort Nasdaq Biotechnology has a 12-month low of $14.05 and a 12-month high of $21.10.

ProShares UltraShort Nasdaq Biotechnology Increases Dividend

The firm also recently declared a dividend, which was paid on Tuesday, December 31st. Investors of record on Monday, December 23rd were issued a $0.2064 dividend. The ex-dividend date was Monday, December 23rd. This is a boost from ProShares UltraShort Nasdaq Biotechnology’s previous dividend of $0.15.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in ProShares UltraShort Nasdaq Biotechnology stock. Jane Street Group LLC acquired a new position in ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 10,520 shares of the company’s stock, valued at approximately $158,000. Jane Street Group LLC owned about 4.78% of ProShares UltraShort Nasdaq Biotechnology at the end of the most recent reporting period.

About ProShares UltraShort Nasdaq Biotechnology

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period.